Gastrohepatic Disorders

Outcomes in men with primary biliary cholangitis may be worse than in women, including a higher risk of death or liver transplantation.

The FDA gave volixibat a special approval as a potential treatment for itching in patients with primary biliary cholangitis.

The U.S. Food and Drug Administration gave accelerated approval for seladelpar to treat primary biliary cholangitis (PBC).

Treatment with obeticholic acid (OCA) improved outcomes for primary biliary cholangitis (PBC) patients in a recent clinical trial.

A phase 2b clinical trial has shown positive preliminary results for volixibat intended for the treatment of PBC.

Ipsen’s Iqirvo (elafibranor) is the first new medicine approved in nearly a decade for the treatment of the PBC, according to a recent press release.

The drug elafibranor appears to be effective and safe for the treatment of primary biliary cholangitis (PBC) in a phase 3 trial.

A randomized survival forest model in machine learning was used to construct a prognostic model for cirrhosis in primary biliary cholangitis (PBC).

A study showed a rare case of primary biliary cholangitis (PBC) with features of autoimmune hepatitis in an adolescent with a genetic defect.

Autotaxin may be an effective noninvasive biomarker for the diagnosis and prognosis of primary biliary cholangitis (PBC), researchers stated.